Dr Allan Marchington
As a Senior Advisor to Apposite, Allan continues to monitor Apposite’s drug discovery and development portfolio. Allan was a Partner at Apposite until October 2015. He serves on the Boards of Calchan and Bird Rock Bio and was also a Director at Ambrx, Ambit, Sotera Wireless, and Convergence Pharmaceuticals. Previously, he was at Abingworth Management, where he was entrepreneur in residence and made strategic changes to several of their portfolio companies. Allan joined Abingworth in 2003 from Millennium Pharmaceuticals, Cambridge Mass., where, as a member of the senior management team, he was responsible for Millennium’s European activities and all of the company’s technology investments. Prior to Millennium, he was principal founder and CEO of Cambridge Combinatorial, a combinatorial chemistry company. Allan worked for seven years in a range of therapeutic areas at Pfizer, Sandwich. He has a PhD in Chemistry from the University of Liverpool.